Site menu

Search by ticker code:
Generic filters

Menu

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Fisher & Paykel Healthcare (ASX:FPH) share price jumps 6% on solid FY24 result, FY25 guidance

The Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) share price has soared 6% in response to the FY24 result.

This company designs, manufactures and sells products and systems used in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea (OSA). Its products are sold in over 120 countries.

FY24 result

Here are some of the highlights for the 12 months to 31 March 2024:

  • Operating revenue grew 10% to $1.74 billion
  • Gross profit increased 11% to $1.04 billion
  • Underlying net profit after tax (NPAT) grew by 6% to $264.4 million
  • Reported NPAT sank 47% to $132.6 million
  • Final dividend increased by 2% to 23.5 cents per share
  • Total dividend grew 2% to 41.5 cents per share

The ASX healthcare share reported 6% growth of hospital operating revenue to $1.1 billion and 18% growth of homecare operating revenue, with 21% growth in OSA mask revenue. These strong growth numbers are helpful for the Fisher & Paykel Healthcare share price.

The company suffered from a $98.1 million negative revaluation of Karaka land, leading to the painful hit to statutory profit. The land value was impacted by its current zoning status, the higher interest-rate environment and general development land market conditions.

Owning the Karaka land “mitigates risk to future growth in light of the current uncertainty around potential development sites in Auckland”. A re-zoning application for the Karaka land will be submitted in 2024.

Net profit was also impacted by the change in New Zealand legislation removing tax deductions for the depreciation of buildings, resulting in a tax expense of $19.3 million to adjust the deferred tax liability balance.

Net profit was also impacted by the voluntary limited recall of Airvo 2 and myAirvo 2 devices manufactured before 14 August 2017. The company had estimated this cost at $12 million, but early responses from customers indicated the number of remaining devices affected by the recall, and the cost of the recall was revised to $20 million.

Outlook for the Fisher & Paykel Healthcare share price

The company provided guidance for FY25. It’s expecting revenue to be in the range of $1.9 billion to $2 billion (up from $1.74 billion), while NPAT is predicted to be between $310 million to $360 million. It reported underlying NPAT of $264.4 million for FY24.

It’s good to see the business is expecting solid growth numbers for the next financial year, though the market has already taken the growth into account, so I wouldn’t call it a hidden opportunity. I’d be happy if I were a long-term shareholder, but I personally wouldn’t choose this moment to invest because of the positivity built into the Fisher & Paykel share price.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content